US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-01 06:58:17 Source:businessViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Swiatek rallies against Haddad Maia to reach Madrid Open semis
Next:California's population grew in 2023, halting 3 years of decline
You may also like
- Refugee agency chief warns that the number of Syrians leaving Lebanon is likely to rise
- Police Minister admits NZ cannot compete with Australian recruitment offer
- Grief and anger in Moscow following concert attack
- US, Japan and South Korea agree to expand security and economic ties at historic Camp David summit
- I'm a psychologist
- How to make sure your leftovers are safe to eat
- Israel Gaza: Journalists injured in al
- Trump asks appeals court to overturn ruling on Georgia prosecutor
- Mom shopping in Target stunned by small print on Clorox wipes